✦ LIBER ✦

Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?

✍ Scribed by Alessandra Marrelli; Paola Cipriani; Vasiliki Liakouli; Francesco Carubbi; Carlo Perricone; Roberto Perricone; Roberto Giacomelli

Book ID: 113482446
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 219 KB
Volume: 10
Category: Article
ISSN: 1568-9972
DOI: 10.1016/j.autrev.2011.04.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Autoantibodies to C-reactive Protein is

Autoantibodies to C-reactive Protein is a Common Finding in SLE, but not in Primary Sjögren's Syndrome, Rheumatoid Arthritis or Inflammatory Bowel Disease

✍ Christopher Sjöwall; Per Eriksson; Sven Almer; Thomas Skogh 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Antibodies to IgG4 Hinge Can Be Found in

Antibodies to IgG4 Hinge Can Be Found in Rheumatoid Arthritis Patients During All Stages of Disease and May Exacerbate Chronic Antibody-Mediated Inflammation

✍ van de Stadt, Lotte A.; de Vrieze, Henk; Derksen, Ninotska I. L.; Brouwer, Mieke 📂 Article 📅 2014 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 247 KB

Contribution of HLA–DRB1 shared epitope

Contribution of HLA–DRB1 shared epitope alleles and chronic inflammation to the increased incidence of cardiovascular disease in rheumatoid arthritis: Comment on the article by Farragher et al

✍ Miguel A. Gonzalez-Gay; Carlos Gonzalez-Juanatey; Javier Llorca; William E. R. O 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 33 KB 👁 2 views

Indirect comparisons of the efficacy of

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

✍ Salliot, C.; Finckh, A.; Katchamart, W.; Lu, Y.; Sun, Y.; Bombardier, C.; Keysto 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 299 KB

Tocilizumab in Patients With Active Rheu

Tocilizumab in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-modifying Antirheumatic Drugs or Tumor Necrosis Factor Inhibitors: Subanalysis of Spanish Results of an Open-label Study Close to Clinical Practice

✍ Álvaro-Gracia, José M.; Fernández-Nebro, Antonio; García-López, Alicia; Guzmán, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 Spanish ⚖ 544 KB

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views